Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle most often associated with the administration of volatile general anesthetic agents and/or the muscle relaxant succinylcholine. MH is likely to be fatal if untreated. In most cases, MH is caused by a defect in the ryanodine receptor.
Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.
